“NASH as per my understanding of LL's MoA is one disease where very strong efficacy is a very likely outcome.”

Yes, the results of the preclinical studies for NASH were very good. Honestly, the NASH trial is a non-factor until later 2021 or early 2022, unless enrollment is fast. CYDY and other biotechs typically enroll trials slowly due to cost and reach.